HCPCS code J3357: Ustekinumab subcutaneous injection billing guide

Key Takeaways

HCPCS code J3357 describes ustekinumab, for subcutaneous injection, 1 mg, and has been active since January 1, 2017.

Each 1 mg of ustekinumab equals 1 billing unit under J3357, so a 45 mg Stelara dose requires 45 units.

J3357 is for subcutaneous use only. IV administration of ustekinumab must be billed under J3358, not J3357.

Pabau’s claims management workflows help dermatology and rheumatology practices track biologic drug billing units and reduce J3357 claim errors.

HCPCS code J3357 is the billing code for ustekinumab (Stelara) given as a subcutaneous injection, priced at 1 mg per billing unit. Coders also search for it as the Stelara J code or the J code for Stelara, and it anchors every claim for in-office Stelara administration.

This is the working Stelara billing and coding guide for J3357: the code description, the billing unit math, the J3357 vs J3358 split, supported diagnosis codes, prior authorization, and the biosimilar Q-codes now replacing the old unclassified-code workaround.

HCPCS code J3357: Description, classification, and effective date

HCPCS code J3357 carries the official long descriptor: Ustekinumab, for subcutaneous injection, 1 mg. It sits within HCPCS Level II, maintained by the Centers for Medicare and Medicaid Services (CMS), under the category Drugs Administered Other than Oral Method (J0013-J8999) and the subcategory Drugs Administered by Injection (J0013-J7175).

According to AAPC Codify, the code falls under the broader J-code drug class for injectable biologics. J3357 became active on January 1, 2017, consistent with Stelara’s expanded FDA-approved indications at that time.

It is a single-source code, meaning it maps exclusively to ustekinumab products indicated for subcutaneous use, including both branded Stelara (manufactured by Janssen) and unbranded biologic versions of ustekinumab administered subcutaneously.

You will see this code written several ways in payer portals and coding tools: the Stelara J code, the J code for Stelara, or even the “Stelara CPT code.” That last label is a common mix-up.

J3357 belongs to HCPCS Level II, the code set that sits alongside CPT on the same claim form, so the accurate term is the Stelara HCPCS code. Whatever the label, subcutaneous ustekinumab bills under J3357.

Practices treating plaque psoriasis, psoriatic arthritis, Crohn’s disease, or ulcerative colitis with ustekinumab will encounter J3357 regularly. Dermatology and rheumatology practices using a buy-and-bill model need accurate unit tracking at the point of administration to avoid downstream claim errors.

Billing units and dose calculation for J3357

Every 1 mg of ustekinumab equals 1 billing unit under J3357. That unit ratio comes directly from the Janssen official billing and coding guide for Stelara and is confirmed in Moda Health’s payer medical necessity criteria. Getting this calculation wrong is one of the most common sources of J3357 claim denials.

Stelara is supplied in two subcutaneous strengths: 45 mg and 90 mg vials and prefilled syringes. The table below shows how billing units map to each standard ustekinumab dose, so your Stelara dosing translates directly into the units on the claim.

The Janssen billing guide explicitly states: “Inaccurate reporting of drug billing units is a common claims error and can result in denied or delayed payment.” Billing 1 unit for a 45 mg dose (rather than 45 units) is a systematic under-reporting error that payers flag during claim review.

Claims management workflows that auto-populate drug units from the administered dose help catch these errors before submission.

J3357 covers the drug only. The injection itself is billed separately with an administration code, usually CPT 96372 for a therapeutic subcutaneous injection given in the office. Pairing the right Stelara injection administration CPT code with J3357 stops the service from being denied as an incomplete claim.

J3357 vs J3358: The subcutaneous vs intravenous distinction

This is the most consequential coding distinction for ustekinumab billing. The Janssen Stelara billing guide states it plainly: STELARA for IV use must NOT be reported with J3357.

The J code for Stelara IV is J3358 (ustekinumab, for intravenous injection, 1 mg), and confusing the two codes generates claim denials and potential compliance exposure.

The IV formulation of ustekinumab is FDA approved for induction dosing in Crohn’s disease and ulcerative colitis. The subcutaneous formulation covers maintenance dosing for those same conditions plus plaque psoriasis and psoriatic arthritis.

A patient starting with IV induction (billed J3358) and transitioning to subcutaneous maintenance (billed J3357) requires two different codes across the treatment cycle.

Good IV therapy documentation practice means the administration route is recorded in the clinical note at every visit. When a billing team processes a claim weeks after the encounter, the route recorded in the chart is the only source of truth for selecting between J3357 and J3358.

Ustekinumab biosimilars and their HCPCS codes: Wezlana, Selarsdi, Yesintek, and more

None of the FDA-approved ustekinumab biosimilars are billed under J3357. That code is reserved for branded Stelara and its authorized subcutaneous versions. Every biosimilar carries its own permanent HCPCS code, so billing one under J3357 is a coding error that generates denials and overpayment recovery requests.

This is where a lot of older guidance is now wrong. Biosimilars like Wezlana were once billed under J3590 (unclassified biologics) while they waited for a permanent code.

CMS assigned each approved ustekinumab biosimilar its own permanent Q-code on a rolling basis through 2025, with the last transition, Starjemza’s Q5164, taking effect July 1, 2026. Every one of those transitions is now in force, so a workflow that still routes any ustekinumab biosimilar to J3490, J3590, or C9399 is out of date.

Here is the current ustekinumab HCPCS crosswalk for the reference product and the most-billed biosimilars.

Two practical notes. When a Q-code descriptor does not name the route, as with Q9998 and Q5100, append the JA modifier for intravenous or the JB modifier for subcutaneous so the payer can tell how the drug was given.

And the list keeps growing: other approved biosimilars, including Otulfi, Imuldosa, and Steqeyma, each carry their own Q-code, so confirm the exact code and NDC for the specific product on the shelf before the claim goes out.

Practices managing multiple biologic agents benefit from drug administration tracking that ties the specific NDC and product name to each clinical encounter record. That link makes biosimilar versus reference-product distinctions auditable at the claim level, so a Stelara claim never goes out under a biosimilar code, or the reverse.

ICD-10 diagnosis codes used with HCPCS code J3357

Payers require a supported ICD-10 diagnosis code to establish medical necessity for ustekinumab claims. The FDA-approved indications for Stelara subcutaneous injection map to four primary condition groups.

Payer policies vary on exactly which ICD-10 codes they accept for medical necessity. Never rely on a generic code list alone: check each payer’s Local Coverage Determination (LCD) or medical necessity criteria document before submitting.

Using a non-covered ICD-10 code, even when the clinical diagnosis is correct, generates an automatic denial that requires appeal. Confirming the diagnosis code is on the payer’s covered list before the claim leaves the practice avoids this entirely.

Prior authorization and payer requirements for J3357

Prior authorization (PA) is required by virtually every major commercial payer and Medicare Advantage plan for ustekinumab. The specific criteria, step therapy requirements, and required documentation vary substantially by payer. No single generalization covers all plans, so treat payer-specific verification as a non-negotiable step before the first dose is administered.

Common PA requirements across major payers (UnitedHealthcare, Aetna, Cigna, Humana) typically include: documented diagnosis meeting the approved indication, evidence of adequate trial and failure of conventional therapies (for psoriasis and IBD), prescriber attestation of disease severity, and a baseline assessment of disease activity. Renewal authorizations often require documented treatment response.

• Verify PA before administering: A dose given without an active authorization generates a claim that payers routinely deny as not pre-authorized, regardless of clinical appropriateness.
• Document step therapy completion: Most commercial plans require documented failure of at least one conventional systemic agent or TNF inhibitor before approving ustekinumab.
• Check Medicare Part B vs. Part D routing: Buy-and-bill (in-office administration) typically routes through Medicare Part B. Patient self-injection may route through Part D. The billing pathway affects which J-code process applies and how reimbursement is calculated.
• Renew authorizations proactively: Ustekinumab maintenance dosing follows a quarterly or every-12-week schedule. Authorization lapses at renewal are a common cause of mid-treatment claim denials.

Maintaining organized med spa compliance documentation practices around prior authorization records, step therapy documentation, and renewal timelines protects the practice from retroactive denials and audit exposure.

Manage biologic drug billing with fewer errors

Pabau's claims management tools help practices track drug units, link NDCs to clinical records, and submit cleaner J-code claims. See how it works for high-cost biologics like ustekinumab.

Book a demo

Medicare reimbursement and fee schedule for J3357

Medicare reimburses J3357 under Part B using Average Sales Price (ASP) methodology when ustekinumab is administered in a physician office or outpatient setting under buy-and-bill. The reimbursement rate is set at ASP plus 6% for most Part B drug codes. CMS updates ASP-based rates quarterly, so the allowable amount for J3357 changes four times per year.

To find the current Medicare allowable amount for J3357, use CMS’s quarterly ASP Drug Pricing Files, not the Physician Fee Schedule Look-up Tool. That tool covers RVU-based physician services, not the ASP-based drug payment limits that apply to J-codes.

Because the rate updates quarterly, coding staff should verify the current allowable before estimating patient cost-share or practice revenue for ustekinumab claims.

The biologic itself drives almost all of the claim value, so the ustekinumab cost per dose runs into the thousands. An accurate J3357 cost estimate depends on pulling the current quarter’s rate rather than last quarter’s.

Biosimilar reimbursement is calculated against the reference product’s average sales price, so a biosimilar’s own list price does not fully dictate what Medicare pays.

Wholesale Acquisition Cost (WAC) is used for reimbursement calculations in some Medicaid programs and certain commercial plans that do not use ASP. WAC-based contracts typically result in lower reimbursement than ASP-plus-6%. Patient adherence documentation tracking treatment response over time also supports authorization renewals and demonstrates medical necessity during payer audits.

Common claim denial reasons and how to correct them

J3357 claims are denied for a predictable set of reasons. Most denials are correctable before resubmission if the documentation in the chart supports the claim.

• Wrong billing units: Billing 1 unit for a 45 mg dose instead of 45 units. Fix: confirm that units on the claim equal the milligrams administered. Resubmit with the corrected unit count and a copy of the administration record.
• Wrong code for route: Submitting J3357 for an IV infusion visit. Fix: verify the route in the clinical note. If IV was administered, recode to J3358 and resubmit with the corrected code.
• Missing or mismatched NDC: Many payers require the NDC number on drug claims. Fix: add the 11-digit NDC from the vial label to the claim in the format required by the payer (typically qualifier N4, then the NDC, then the quantity and unit).
• Prior authorization not active: The claim date of service falls outside the authorized period. Fix: confirm authorization dates against the date of service. Appeal with proof that authorization was obtained or file for retro-authorization per the payer’s policy.
• Non-covered ICD-10 code: The diagnosis code submitted is not on the payer’s covered code list for J3357. Fix: review the payer’s LCD or medical necessity criteria, select the most accurate covered code, and resubmit with an amended claim if appropriate.
• Wrong product coded: Billing J3357 for a biosimilar such as Wezlana or Pyzchiva. Fix: confirm the NDC, identify the correct product, and recode to that biosimilar’s own Q-code (for Wezlana, Q5137 for subcutaneous or Q5138 for intravenous) with the matching NDC.

Maintaining HIPAA-compliant billing records that tie the specific drug product, NDC, administered dose in milligrams, and route to each clinical encounter creates a clean audit trail for denial appeals and compliance reviews.

Ensure your billing team can pull the clinical note and match it to the claim within minutes of receiving a denial. Practices using HIPAA compliance software that connects the clinical record to the claim workflow reduce the manual reconciliation burden substantially.

Buy-and-bill vs specialty pharmacy channel for HCPCS code J3357

The channel through which ustekinumab is dispensed determines who bills J3357. Under buy-and-bill, the practice purchases Stelara directly, administers it in-office, and submits the J3357 claim to the payer.

Under the specialty pharmacy channel, the pharmacy dispenses the drug to the patient for self-injection at home, and typically handles billing through the patient’s Part D or specialty pharmacy benefit.

Buy-and-bill creates practice revenue through the spread between the acquisition cost and the ASP-based Medicare reimbursement, but it also creates inventory risk and cash flow exposure between purchase and reimbursement. Specialty pharmacy eliminates that inventory burden but also eliminates the in-office drug margin. Many gastroenterology and dermatology practices mix both channels depending on patient insurance and benefit design.

Only the buy-and-bill model generates a Part B J3357 claim submitted by the practice. If a patient self-injects at home using a specialty pharmacy supply, the practice does not submit J3357.

Confirming the dispensing channel before building the billing workflow for a new ustekinumab patient avoids errors that occur when staff assumes buy-and-bill when the drug is actually being handled through specialty pharmacy.

Practices tracking channel-specific billing can use digital intake forms to document the dispensing pathway at the start of each treatment.

Looking up and verifying HCPCS code J3357

Several free and paid tools let billing staff verify J3357 code properties, check crosswalks, and look up current fee schedule amounts. The AAPC Codify HCPCS lookup provides code descriptors, category placement, and crosswalk references for J3357.

For a free CMS-data-based lookup, PGM Billing’s lookup tool returns code descriptions and basic properties without a subscription. The Medicare Informatics code tables provide a tabular reference for the full J-code range, including J3357.

For NDC-to-HCPCS crosswalk verification, the HIPAASpace HCPCS-to-NDC mapping tool (hipaaspace.com) lists associated NDC codes for J3357. Always verify that the NDC on your claim matches a recognized mapping for J3357 before submission, as payers use NDC validation to confirm the correct HCPCS code was selected.

For quick reference, the subcutaneous Stelara NDC codes billed against J3357 are 57894-0060-02 (45 mg single-dose vial), 57894-0060-03 (45 mg prefilled syringe), and 57894-0061-03 (90 mg prefilled syringe). Matching the J3357 NDC on the claim to the strength actually administered is the fastest way to confirm the pairing a payer expects.

The practice management software your team uses should support HCPCS code lookup, drug unit auto-population from administered doses, and NDC capture from inventory records.

Practices running separate EMR and billing systems often encounter unit and NDC mismatches that only surface after a claim denial, by which point the chart has been filed and the discrepancy requires manual reconciliation.

Conclusion

Billing ustekinumab accurately under HCPCS code J3357 requires getting three things right consistently: the billing units (1 unit per mg administered), the correct code for the route (J3357 for subcutaneous, J3358 for IV), and the supported ICD-10 diagnosis code for the payer’s covered indication list. A single error on any of these elements generates a denial on a multi-thousand-dollar claim.

Pabau’s medical records management connects clinical encounter data to the billing workflow, reducing the manual reconciliation that causes unit miscounts and code mismatches. To see how Pabau handles biologic drug billing for dermatology, gastroenterology, and rheumatology practices, book a demo with our team.

Continue your research

Coding another injectable biologic claim? J9000 breaks down billing units, dosage calculation, and the most common denial fixes.

Need the same billing-unit math for a different chemotherapy drug? J9264 covers dose-to-unit conversion, ICD-10 pairing, and denial troubleshooting.

Billing a wound care supply code instead? Q4101 covers billing units, NDCs, and payer documentation requirements.

Frequently asked questions